Several well-designed, randomized trials and registries have recently been
completed in patients undergoing percutaneous coronary intervention (PCI) f
or the treatment of symptomatic coronary artery disease. These studies have
further clarified the value of newer pharmacologic and mechanical approach
es to patients with atherosclerotic disease and have resulted in improved c
linical outcomes in patients undergoing PCI, As a result, many of the older
paradigms of lesion-specific device selection have been revised to include
the intricate balance of devices and drugs, tailored to the specific clini
cal presentation and lesion morphology in patients undergoing PCI, This art
icle reviews several recent clinical trials and discusses their impact on e
arly and late outcomes in patients undergoing PCI for symptomatic coronary
artery disease. Curr Opin Cardiol 1999, 14:412-418 (C) 1999 Lippincott Will
iams & Wilkins, Inc.